NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been given an average rating of "Moderate Buy" by the six analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $16.60.

Several brokerages recently issued reports on NPCE. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $17.00 price objective on shares of NeuroPace in a report on Wednesday, May 14th. HC Wainwright began coverage on NeuroPace in a report on Wednesday, May 28th. They set a "buy" rating and a $18.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. Zacks Research cut NeuroPace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Finally, Wells Fargo & Company reduced their price objective on NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th.

NeuroPace Stock Performance

Shares of NPCE stock opened at $8.42 on Tuesday. The stock has a 50 day simple moving average of $9.82 and a 200-day simple moving average of $11.66. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.98. The company has a current ratio of 5.47, a quick ratio of 4.51 and a debt-to-equity ratio of 3.02. The company has a market cap of $278.53 million, a price-to-earnings ratio of -10.02 and a beta of 1.89.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $23.52 million during the quarter, compared to analysts' expectations of $23.08 million. NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. On average, equities analysts forecast that NeuroPace will post -1 EPS for the current year.

Institutional Investors Weigh In On NeuroPace

A number of large investors have recently bought and sold shares of NPCE. Ameritas Investment Partners Inc. grew its holdings in NeuroPace by 83.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock valued at $27,000 after buying an additional 1,118 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in NeuroPace in the 4th quarter valued at $29,000. Legal & General Group Plc raised its holdings in NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock valued at $30,000 after acquiring an additional 1,239 shares during the last quarter. Quantbot Technologies LP acquired a new position in NeuroPace in the 2nd quarter valued at $35,000. Finally, GAMMA Investing LLC acquired a new position in NeuroPace in the 1st quarter valued at $53,000. Institutional investors and hedge funds own 78.83% of the company's stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.